Home > Boards > US Listed > Medical - Equipment >

Akers Biosciences Inc. (AKER)

AKER RSS Feed
Add AKER Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 5/4/2021 5:37:30 PM - Followers: 96 - Board type: Free - Posts Today: 0





http://www.akersbio.com/about/company-overview

Akers Biosciences mission is dedicated to solving global health challenges. Akers was founded in 1989 and has over
30 years of success in the health diagnostic industry having developed proprietary, in vitro diagnostic technologies.

In March of 2020, in an attempt to further their mission, Akers announced a strategic partnership with Premas Biotech.
The partnerships primary objective is to focus on novel vaccine candidates.
The emergence of this pandemic offers an opportunity for the company to be a solution in the healthcare space,
one that sets the stage for our next chapter of growth.

http://www.akersbio.com/vaccine/conference-call

Conference Call – Licensing

Akers Biosciences Schedules Conference Call to Discuss Licensing Announcement with Premas Biotech for a Coronvirus Vaccine Candidate

Listen to the replay of the call

Transcript

http://www.akersbio.com/vaccine/covid-19-vaccine-candidate

Covid-19 Vaccine Candidate

Premas develops novel & transformational technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates.
Akers licensed a novel coronavirus vaccine candidate under development by Premas using Premas’ genetically engineered S. cerevisiae platform, D-Crypt™.

The Premas platform has three key advantages which will set this vaccine candidate apart from industry peers.

  • Premas has previously expressed more than 30 proteins of similar profile to those in the structure of Covid-19,
    therefore the platform is well suited for the expression of difficult vaccine candidate proteins.
    The technology platform is highly scalable with a robust process, which should represent significant cost savings compared to other similar vaccine platforms.
    The current global pandemic might allow for an expedited FDA review timeline based on recent pronouncements regarding other Covid-19 vaccine and treatment candidates.

Premas successfully cloned three Coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) in the first quarter of 2020 which further differentiates our vaccine candidate.
We aim to provide the immune system with several opportunities to identify the virus; a design concept extremely important for efficacy and our future success.

We held a conference call with Prabuddha Kundu, Co-Founder and Managing Director at Premas Biotech, in late March.
The transcript, which provides additional information on our philosophy and milestone timeline, can be accessed here.

 

Notice of Settlement – to current Akers Stockholders

 

 

Particle Immuno-Filtration Assay (PIFA®) Technology

PIFA® technology is a cutting-edge, patented immunoassay method which rapidly, easily, and accurately detects target antigens or antibodies.

How It Works

PIFA® technology is based on the selective filtration of microparticles in response to antibody/antigen binding.
Dyed microparticles coated with antigens or antibodies determine the visual signal for the results of the assay.
The presence of a corresponding antibody or antigen in the test sample results in the formation of a matrix of microparticles, which are more susceptible to filtration.
The inability of these matrixed microparticles to move through the filter, and the resulting color change in the reagent mixture,
signal positive reactivity of the test sample (e.g. the presence of target antigens or antibodies).

Key features of PIFA® technology make it advantageous for a broad array of uses:

  • Accuracy rivaling or surpassing current laboratory methods
    Rapid Results, typically within 1 to 5 minutes
    Point-of-care compatibility
    Easy to use
    Easy to dispose

PIFA® technology is currently used in:

Licensing Availability

PIFA® technology is available for licensing. To inquire about licensing or for technical inquiries, please contact us.

Patent Information

 





https://finviz.com/quote.ashx?t=aker&ty=c&ta=1&p=d
 
Shs Outstand 8.72M
Shs Float 8.30M
Short Float 2.14%
Insider Own 0.83%
Insider Trans -0.83%
Inst Own 4.30%
Book/sh 2.96
Cash/sh 2.00
Debt/Eq     NO DEBT 0.00
52W Range 1.55 - 12.72


[-chart]finviz.com/chart.ashx?t=AKER&ty=c&ta=1&p=d&s=l[/chart]



https://finviz.com/chart.ashx?t=AKER&ty=c&ta=1&p=d&s=l






$AKER  https://www.otcmarkets.com/stock/AKER/disclosure

https://www.otcmarkets.com/stock/AKER/news

https://www.otcmarkets.com/stock/AKER/security

https://www.otcmarkets.com/stock/AKER/profile

https://www.otcmarkets.com/stock/AKER/quote

https://www.otcmarkets.com/stock/AKER/overview







*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.






 
AKER
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AKER News: Contango Announces the Appointment of Two New Directors 04/29/2021 04:10:00 PM
AKER News: Securities Registration Statement (simplified Form) (s-3/a) 04/28/2021 05:26:41 PM
AKER News: Statement of Beneficial Ownership (sc 13d) 04/27/2021 06:02:14 AM
AKER News: Current Report Filing (8-k) 04/22/2021 06:04:24 AM
AKER News: Statement of Changes in Beneficial Ownership (4) 04/21/2021 05:55:31 PM
PostSubject
#2221   MYMD-1 TO THE RESCUE !!!!! SeanVan 05/04/21 05:37:30 PM
#2220   https://investorshub.advfn.com/MYMD-MYMD-39405/ knuts4oe 04/19/21 02:07:13 PM
#2219   Seasoned executive team with a track record of SeanVan 04/19/21 01:13:47 PM
#2218   MyMD Pharmaceuticals Begins Trading on Nasdaq.. SeanVan 04/19/21 01:13:34 PM
#2217   DONE MikeSailMikeSail 04/19/21 12:21:23 PM
#2216   MyMD Pharmaceuticals Scientific Advisory Board leifsmith 04/19/21 10:43:47 AM
#2215   Can the name of this board be changed? leifsmith 04/19/21 09:54:46 AM
#2214   "Significantly increasing lifespan" —MyMD Pharmaceuticals leifsmith 04/19/21 09:47:47 AM
#2213   We need a MYMD iHub board. leifsmith 04/19/21 09:33:43 AM
#2212   Bid/Ask interesting - chaotic for awhile looks like leifsmith 04/19/21 09:32:12 AM
#2211   MYMD Begins Trading this Morning leifsmith 04/19/21 09:29:18 AM
#2210   Extremely reasonable!! knuts4oe 04/17/21 10:56:50 AM
#2209   Reason for the phase 2 trial target? leifsmith 04/16/21 01:58:28 PM
#2208   Merger approved. MYMD to start trading April 19, 2021 leifsmith 04/16/21 01:53:42 PM
#2207   When I said "Fasten your seat belts!", I knuts4oe 04/13/21 05:24:45 PM
#2206   Today's announcement seemed to miss most of the leifsmith 04/13/21 04:43:39 PM
#2205   WHAT HATH JONNIE WROUGHT !! I am knuts4oe 04/12/21 12:50:17 PM
#2204   Yes, we go ... leifsmith 04/12/21 10:50:08 AM
#2203   HERE WE GO !!!!! knuts4oe 04/12/21 10:06:04 AM
#2202   knuts, The main difference is MyMD-1 is ready to SeanVan 03/31/21 07:17:46 PM
#2201   Hard to believe! On 03/11/21 Jonnie and knuts4oe 03/29/21 09:41:22 PM
#2200   From a competitive point of view I see knuts4oe 03/29/21 07:27:05 PM
#2199   Looks interesting. Complimentary rather than competitive, except in leifsmith 03/29/21 03:14:33 PM
#2198   Those who are serious about MyMD Pharma should knuts4oe 03/29/21 10:24:23 AM
#2197   Correction of my previous post. Jonnie Williams appears leifsmith 03/27/21 11:19:17 PM
#2196   Today I received a request for my votes leifsmith 03/27/21 01:05:05 PM
#2195   Leif, Agree. But, Shelf offerings can dilute existing SeanVan 03/26/21 11:50:20 PM
#2194   You may be right, but not this is leifsmith 03/26/21 07:31:19 PM
#2193   $AKER: The reasons mentioned to raise $100 millions SeanVan 03/26/21 06:37:05 PM
#2192   Could be wrong, of course, but I think leifsmith 03/24/21 11:59:34 AM
#2191   Lief, Do you think the merger is going to SeanVan 03/24/21 11:13:05 AM
#2190   Anyone interested in the future of AKER should leifsmith 03/24/21 09:46:45 AM
#2189   Here is the latest website for MyMD for knuts4oe 03/23/21 10:09:31 AM
#2188   Williams, Hopkins, McNulty, O'Donnell leifsmith 03/22/21 09:20:52 AM
#2187   Stockholder meeting, Apr 15, & merger information leifsmith 03/22/21 08:12:46 AM
#2186   Very interesting. Thanks! leifsmith 03/22/21 08:10:18 AM
#2185   As has been revealed, Supera Pharma will be knuts4oe 03/21/21 12:21:46 PM
#2184   Can't seem to get it to open, but knuts4oe 03/15/21 09:39:01 PM
#2183   Since MyMD has not yet announced any knuts4oe 03/15/21 09:11:35 PM
#2182   Jonnie must have a passion for breeding rabbits leifsmith 03/15/21 10:56:42 AM
#2181   Looks like all these companies have as their knuts4oe 03/15/21 10:15:17 AM
#2180   Here is yet another new FL company whose knuts4oe 03/15/21 09:55:57 AM
#2179   knuts4oe, grateful for your research - substantial findings leifsmith 03/15/21 09:21:51 AM
#2178   That's fascinating. Thanks! leifsmith 03/15/21 09:08:10 AM
#2177   Everyone seen this - knuts4oe 03/14/21 09:06:31 PM
#2176   OOPS! knuts4oe 03/13/21 12:17:26 PM
#2175   At the risk of repetition just noticed that knuts4oe 03/13/21 12:13:19 PM
#2174   While we can rule out Covid-19 as the knuts4oe 03/12/21 05:24:26 PM
#2173   As you know, the company never said it leifsmith 03/12/21 01:41:18 PM
#2172   $AKER The reverse merger with MYMD paper SeanVan 03/11/21 01:50:59 PM
PostSubject
Consent Preferences